Key Takeaways
- • JW Holdings acquired 100% equity stake in Solidus Investment from Cha Bio Group for 30.6 billion won ($20.4 million), representing a 17% control premium over net asset value as of September 2025.
- • The acquisition expands JW Holdings' subsidiary count to seven and constitutes 2.45% of the holding company's total assets, providing immediate access to an established mid-sized venture capital platform.
- • Solidus Investment is a biotech-focused venture capital firm with portfolio companies including Alteogen and Orum Therapeutics, enabling JW to strengthen its license-in drug strategy and investment capabilities.
- • The transaction allows Cha Bio Group to monetize a non-core asset while JW Holdings absorbs the investment team and operational expertise as an alternative to building a venture capital capability from scratch.
- • The 17% control premium paid aligns with typical South Korean venture capital market transaction multiples, positioning JW's acquisition as a market-rate strategic consolidation rather than an outlier valuation.
Summary
JW Holdings, the holding company of JW Pharmaceutical, completed the acquisition of venture capital firm Solidus Investment from Cha Bio Group for 30.6 billion won ($20.4 million) on March 16, 2026, according to Financial Supervisory Service filings. The transaction granted JW Holdings full equity control of Solidus Investment, which had been collectively held by four Cha Group affiliates: Cha Biotech (46.5%), Cha Care (29.6%), CMG Pharmaceutical (20%), and Sungkwang Medical Foundation (3.9%). Cha Biotech, the largest shareholder, received approximately 14.2 billion won ($9.5 million) from the sale.
The acquisition price reflects a 17% control premium over Solidus Investment's net asset base of 26.1 billion won ($17.4 million) as of September 2025, placing the transaction within the standard 15-20% premium range typical of South Korean venture capital market transactions. Industry precedent includes NeoPlux' acquisition by Shinhan Venture Investment and Daol Investment's 33% premium acquisition by Woori Financial Group, contextualizing JW's valuation as market-aligned. The transaction adds Solidus Investment as JW Holdings' seventh subsidiary and represents 2.45% of the holding company's total asset base.
Solidus Investment operates as a biotech-focused venture capital firm with portfolio holdings that include Alteogen and Orum Therapeutics, complementing JW Pharmaceutical's stated strategy to expand through license-in drug acquisition and investment diversification. The acquisition strategy reflects JW's preference for acquiring operational venture capital infrastructure and existing expertise rather than building internal capabilities organically. For Cha Bio Group, the sale provided immediate liquidity for a non-core subsidiary while allowing JW to deploy capital into established investment management operations with ready-made deal flow and sector expertise.
The transaction aligns with JW Pharmaceutical's broader international expansion strategy, which has included acquisitions in pharmerging markets—most notably a Vietnamese pharmaceutical plant acquisition—and recent strategic partnerships such as an agreement with U.S. venture capital firm ARCH Venture Partners announced in March 2026 to strengthen open innovation and deal sourcing capabilities. The Solidus Investment acquisition strengthens JW's position within the Korean biotech investment ecosystem while providing financial leverage to pursue additional license-in opportunities and portfolio company investments.
The acquisition price reflects a 17% control premium over Solidus Investment's net asset base of 26.1 billion won ($17.4 million) as of September 2025, placing the transaction within the standard 15-20% premium range typical of South Korean venture capital market transactions. Industry precedent includes NeoPlux' acquisition by Shinhan Venture Investment and Daol Investment's 33% premium acquisition by Woori Financial Group, contextualizing JW's valuation as market-aligned. The transaction adds Solidus Investment as JW Holdings' seventh subsidiary and represents 2.45% of the holding company's total asset base.
Solidus Investment operates as a biotech-focused venture capital firm with portfolio holdings that include Alteogen and Orum Therapeutics, complementing JW Pharmaceutical's stated strategy to expand through license-in drug acquisition and investment diversification. The acquisition strategy reflects JW's preference for acquiring operational venture capital infrastructure and existing expertise rather than building internal capabilities organically. For Cha Bio Group, the sale provided immediate liquidity for a non-core subsidiary while allowing JW to deploy capital into established investment management operations with ready-made deal flow and sector expertise.
The transaction aligns with JW Pharmaceutical's broader international expansion strategy, which has included acquisitions in pharmerging markets—most notably a Vietnamese pharmaceutical plant acquisition—and recent strategic partnerships such as an agreement with U.S. venture capital firm ARCH Venture Partners announced in March 2026 to strengthen open innovation and deal sourcing capabilities. The Solidus Investment acquisition strengthens JW's position within the Korean biotech investment ecosystem while providing financial leverage to pursue additional license-in opportunities and portfolio company investments.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.